The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

A $100 million gift establishes a UChicago institute focused on microbiome and immunity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS
Members of the Duchossois Family Foundation, including (back row, from left) Craig Duchossois, Janet Duchossois, Ilaria Woodward, Jessica Swoyer Green, Dayle Duchossois Fortino, (seated, from left) Ashley Joyce, Richard Duchossois and Kimberly Duchossois. Photo by Richard Shay

The University of Chicago received a $100 million gift that will establish The Duchossois Family Institute: Harnessing the Microbiome and Immunity for Human Health.

The institute will bring together the university’s strengths in genetics, immunology, microbiome research, and computation to develop research and interventions focused on optimizing health.

The gift was made by the Duchossois Group Inc. Chairman and CEO Craig Duchossois, his wife Janet Duchossois, and The Duchossois Family Foundation.

The Duchloss family first provided support to UChicago in 1980, when Richard Duchossois established the Beverly E. Duchossois Cancer Fund in memory of his wife. In the years since, the family has given $37 million to the medical center to drive innovation and transformative care, including a named professorship and several cancer research funds, as well as a $21 million gift in 1994 to establish the Duchossois Center for Advanced Medicine.

The Duchossois gift is the single largest in support of UChicago Medicine, and it is the fourth gift of $100 million or more to the University of Chicago.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
By Jacquelyn Cobb and Sara Willa Ernst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account